Company Overview and News

2
Cadila Healthcare Limited - Press Release

2018-06-19 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532321 CDLYY CADILAHC

2
Cadila Healthcare Limited - Investor Presentation

2018-06-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532321 CDLYY CADILAHC

19
Market Update: Pharma stocks extend gains with Lupin up 5%; TCS, RIL most active

2018-06-12 moneycontrol
The broader indices are trading on a positive note this Tuesday afternoon with the Nifty trading higher by 47 points at 10,834 and the Sensex added 177 points at 35,661.
500408 500325 AUROPHARMA RELIANCE TTQQY 532714 HINDUNILVR 511389 VIDEOIND IDBLZ HCL-INSYS CADILAHC TATACHEM 532960 JUSTDIAL 532321 535648 532187 532483 RIGD 500696 500179 BJJQY KEC 500770 RLNIY 500034 SBAZ UBNC 524804 INDUSINDBK IBVENTURES CDLYY CNRYY BAJFINANCE ARBQY TATAELXSI CANBK JSTQY

11
Market Update: PSU banks, pharma stocks rally with RIL up 1%; Infosys hits fresh 52-week high

2018-06-12 moneycontrol
The broader indices are trading on a positive note this Tuesday afternoon with the Nifty trading higher by 60 points at 10,848 and the Sensex added 214 points at 35,705.
500408 500325 AUROPHARMA RELIANCE 532714 511389 VIDEOIND HCL-INSYS CADILAHC 532321 532187 RIGD 500179 BJJQY KEC RLNIY 500034 SBAZ UBNC 524804 INDUSINDBK CDLYY BAJFINANCE ARBQY TATAELXSI

22
Market Update: Nifty pharma sprints ahead as Sun Pharma zooms 8%; Bajaj Finance hits new 52-week high

2018-06-08 moneycontrol
The broader indices continue to trade on a negative note this Friday afternoon but managed to regained some lost ground with the Nifty trading lower by 11 points at 10,757 and the Sensex shed 41 points at 35,422.
500408 IOB 500325 AUROPHARMA FSL RELIANCE 532418 TCHQY 532755 511389 VIDEOIND TTNQY CADILAHC 532388 532321 500470 532540 532461 RIGD BJJQY 500570 TATAMOTORS RLNIY 500034 UBNC 532809 524804 VTUWY CDLYY 539207 TECHM 533269 BAJFINANCE TTST PNJZY TATASTEEL TATLY SINTEX ARBQY 502742 TATAELXSI TCS PNB MANPASAND WABAG ANDHRABANK TTM

16
11
Sensex ends over 275 points higher, Nifty near 10,700 after RBI hikes repo rate

2018-06-06 moneycontrol
A three-day losing streak broken and how! Equity benchmarks had a good day of trade, with the Sensex closing 275 points higher, while the Nifty closed near 10,700-mark.
500820 TCHQY HIN ASIANPAINT 532755 CADILAHC CDLYY TECHM 532321 HDB 500180 HDFCBANK 500570 500185 TATAMOTORS HCC TTM

2
Cadila Healthcare Limited - Press Release

2018-06-06 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532321 CDLYY CADILAHC

25
Market Live: Nifty extends losses, Sensex falls 200 pts; Nifty Bank sheds 400 pts

2018-06-04 moneycontrol
DHFL raises nearly Rs 11,000 crore: Housing financier DHFL has raised over Rs 10,944 crore through public issue of bonds which had open for subscription in May.
500325 500820 RELIANCE 532978 BHRQY ASIANPAINT CADILAHC 532321 PAPERPROD RIGD HDFCBANK 500570 BHARTIARTL TATAMOTORS 509820 RLNIY KMBKY IBN CDLYY 532454 ICICIBANK BAJAJFINSV HDB 532174 500180 KOTAKBANK 500247 TTM

32
Market Live: Sensex slips 100 pts, Nifty Bank dips 250 pts; advance:decline ratio 3:1

2018-06-04 moneycontrol
Earnings in the final quarter of FY18 were marked by sustained traction and the prospect of capex in consumption-facing businesses, infrastructure spending by the government, and strong growth in commodity-driven companies and digital-ready information technology players.
500325 RELIANCE 533278 CADILAHC 532321 PAPERPROD 532187 ANANTRAJ RIGD 526521 HDFCBANK HEROMOTOCO BJJQY SANGHIIND 500570 TATAMOTORS CLNDY 509820 RLNIY 500034 515055 INDUSINDBK IBN CANFINHOME 511196 CDLYY 500182 ICICIBANK BAJFINANCE HDB 532174 500180 HRTQY COALINDIA TTM

34
Market Live: Nifty struggles below 10,700; HDFC Bank, PC Jeweller most active

2018-06-04 moneycontrol
Nikhil Kamath, Co-founder, Zerodha, said quality of the auditing firm is something people should pay heed to. "An auditor who resigns at the last minute, especially without reason, should definitely be penalised."
500325 RELIANCE 533278 CADILAHC 532321 532187 ANANTRAJ RIGD 526521 HDFCBANK HEROMOTOCO BJJQY SANGHIIND 500570 TATAMOTORS CLNDY RLNIY 500034 SBAZ 515055 INDUSINDBK KMBKY IBN CANFINHOME 511196 CDLYY 500182 ICICIBANK BAJFINANCE HDB 532174 500180 KOTAKBANK 534809 HRTQY 500247 PCJEWELLER COALINDIA TTM

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...